ACNS1721: A Phase 2 Study of Veliparib (ABT-888 IND # 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Brief description of study

You are being asked to take part in this research study because you have been diagnosed with a type of cancer called high-grade glioma (HGG). A glioma is a type of cancer that grows as a tumor in the brain. A glioma is considered “high-grade” when it is growing and spreading quickly. You previously enrolled on another study called APEC14B1 and consented for pre-screening to be done on that study. Those tests looked for certain genetic changes (called mutations) in your cancer cells called H3 K27M and BRAFV600E. The pre-screening tests confirmed that you have an HGG without the H3 K27M and BRAFV600E mutations. Because of this, the study doctors have determined that you are eligible for this study, ACNS1721.


Clinical Study Identifier: s19-00007
ClinicalTrials.gov Identifier: NCT03581292
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.